Ameritas Investment Partners Inc. acquired a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,475 shares of the company’s stock, valued at approximately $28,000.
Several other institutional investors also recently made changes to their positions in CLPT. The PNC Financial Services Group Inc. acquired a new stake in shares of ClearPoint Neuro in the first quarter worth $42,000. Clarus Group Inc. acquired a new stake in shares of ClearPoint Neuro in the first quarter worth $135,000. BlackRock Inc. boosted its stake in ClearPoint Neuro by 565.9% during the first quarter. BlackRock Inc. now owns 320,087 shares of the company’s stock worth $6,767,000 after buying an additional 272,022 shares in the last quarter. Royce & Associates LP acquired a new stake in ClearPoint Neuro during the first quarter worth $1,165,000. Finally, UBS Group AG boosted its stake in ClearPoint Neuro by 11.7% during the first quarter. UBS Group AG now owns 14,406 shares of the company’s stock worth $305,000 after buying an additional 1,505 shares in the last quarter. Institutional investors and hedge funds own 23.23% of the company’s stock.
Separately, B. Riley reiterated a “buy” rating on shares of ClearPoint Neuro in a research note on Wednesday, August 11th.
Shares of NASDAQ:CLPT opened at $19.62 on Friday. ClearPoint Neuro, Inc. has a 52 week low of $4.87 and a 52 week high of $31.29. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.81 and a current ratio of 15.62. The company’s fifty day moving average is $18.94 and its 200-day moving average is $19.30. The company has a market capitalization of $438.84 million, a PE ratio of -40.87 and a beta of 1.00.
ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Monday, August 9th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.03). ClearPoint Neuro had a negative net margin of 63.68% and a negative return on equity of 39.58%. The firm had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.47 million.
ClearPoint Neuro Profile
Clearpoint Neuro, Inc engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform comprises of ClearPoint system and ClearTrace system.
Recommended Story: How to execute a trade ex-dividend strategy?
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.